Xoma Files US IND On Hu1124 As A Psoriasis Treatment

15 September 1996

California, USA-based Xoma Corp has filed an Investigational New Drug application with the US Food and Drug Administration for clinical testing of hu1124 in patients with moderate-to-severe psoriasis.

Previously referred to as anti-CD11a, hu1124 is a humanized monoclonal antibody that Xoma is developing in collaboration with Genentech for psoriasis and other indications, including organ transplant rejection. The planned trial will test the safety of the product in 30-40 psoriasis patients in multiple dosage groups. The filing comes less than five months from the start of the collaborative project and, says Genentech's executive vice president John McLaughlin, "confirms our opinion of Xoma's capability."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight